Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 16/20 | 0.64 |
| ▸ | THRB | P10828 | 16/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PCNA | P12004 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044554 | 0.90 | THRA (0.53) | THRATHRBGRIN2DGRIN3BGRIN1 | |
| SCHEMBL4204815 | 0.80 | THRA (0.51) | THRATHRBESR1ESR2 | |
| SCHEMBL283169 | 0.80 | THRA (0.69) | THRATHRBESR1ESR2GRIN2D | |
| SCHEMBL4963440 | 0.78 | THRA (0.66) | THRATHRBESR1ESR2GRIN2D | |
| SCHEMBL282249 | 0.78 | THRB (1.00) | THRATHRB | |
| SCHEMBL282128 | 0.77 | THRB (0.79) | THRATHRB | |
| SCHEMBL4204817 | 0.76 | THRA (0.45) | THRATHRBESR1ESR2POLB | |
| SCHEMBL283584 | 0.76 | THRB (0.82) | THRATHRBESR1ESR2 | |
| SCHEMBL281929 | 0.76 | THRA (0.63) | THRATHRBHIF1A | |
| SCHEMBL3153210 | 0.75 | THRA (0.62) | THRATHRBESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11202789-B2 | Method of treating glycogen storage disease | VIKING THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | VIKING THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20190343850-A1 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE | VIKING THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707472-B2 | Compositions for the treatment of fibrosis | COL2A1, TGFBR2, COL1A1 | THRA 251/4885THRB 33/4885ESR1 619/4885 |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | COL2A1, TGFBR2, COL1A1 | THRA 251/4885THRB 33/4885ESR1 619/4885 |
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | TSHR, TPO, THRA | THRA 3/4885THRB 4/4885ESR1 2768/4885 |
| US-11202789-B2 | Method of treating glycogen storage disease | GYS2, GYS1, PYGL | THRA 9/4885THRB 7/4885ESR1 2163/4885 |
| US-20190343850-A1 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE | GYS2, GYS1, PYGL | THRA 9/4885THRB 7/4885ESR1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.